ENTROLATE
Main information
- Trade name:
- ENTROLATE 10 TAB
- Active ingredient:
- Diloxanide Furoate,Tinidazole
- Available from:
- Stadmed
- Dosage:
- 500,300;MG
- Pharmaceutical form:
- TAB
- Composition:
- 10
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Fluticasone furoate / umeclidinium bromide / vilanterol trifenatate, Therapeutic area: Pneumology-allergology
Europe - EFSA - European Food Safety Authority EFSA Journal
12-6-2018
Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 1, Authorised
Europe - EMA - European Medicines Agency
12-6-2018
Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 1, Authorised
Europe - EMA - European Medicines Agency
7-6-2018
Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 15, Authorised
Europe - EMA - European Medicines Agency
6-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Indacaterol (acetate) / mometasone (furoate), Therapeutic area: Pneumology-allergology
Europe - EFSA - European Food Safety Authority EFSA Journal
30-5-2018
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
17-5-2018
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
3-7-2018
Revinty Ellipta (Glaxo Group Ltd)
Revinty Ellipta (Active substance: fluticasone furoate / vilanterol) - Corrigendum - Commission Decision (2014)3040 of Tue, 03 Jul 2018
Europe -DG Health and Food Safety
3-7-2018
Relvar Ellipta (Glaxo Group Ltd)
Relvar Ellipta (Active substance: fluticasone furoate/vilanterol) - Corrigendum - Commission Decision (2013)8089 of Tue, 03 Jul 2018
Europe -DG Health and Food Safety
3-5-2018
Avamys (Glaxo Group Ltd)
Avamys (Active substance: Fluticasone furoate) - Centralised - Yearly update - Commission Decision (2018)2773 of Thu, 03 May 2018
Europe -DG Health and Food Safety
26-1-2018
Pending EC decision: Relvar Ellipta, fluticasone furoate / vilanterol, Opinion date: 25-Jan-2018
Europe - EMA - European Medicines Agency
25-1-2018
Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 0, Authorised
Europe - EMA - European Medicines Agency
12-1-2018
Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 0, Authorised
Europe - EMA - European Medicines Agency